Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 22 lut 2016 · Blood flow rate (BFR) during HD is one of the important determinants of increasing dialysis dose. However, the optimal BFR is unclear. In this study, we investigated the impact of the BFR on all-cause mortality in chronic HD patients.

  2. 17 paź 2019 · Abstract. This guideline is written primarily for doctors and nurses working in dialysis units and related areas of medicine in the UK, and is an update of a previous version written in 2009. It aims to provide guidance on how to look after patients and how to run dialysis units, and provides standards which units should in general aim to achieve.

  3. Many studies elucidate the blood flow rate effect on hemodialysis adequacy, while less consideration have given to the types of flux membrane and complications.

  4. 4 cze 2024 · In this systematic review of nine studies and meta-analysis of four studies involving 576 adult patients with kidney failure receiving maintenance HD, we found that increasing dialysate flow rates from 500 ml/min to 800 ml/min improved dialysis adequacy as measured by URR (3.38) and spKt/V (0.08).

  5. 28 lis 2023 · This topic will address diagnosis and management of side effects and complications related to intrauterine contraception in a temporal fashion broken down by typical onset of presentation in relation to timing from intrauterine device (IUD) insertion.

  6. 26 cze 2023 · Objectives: Identify the anatomical structures, indications, and contraindications of IUD placement and removal. Describe the equipment, personnel, preparation, and technique in regards to IUD placement and removal. Outline the appropriate evaluation of the potential complications and clinical significance of IUD placement and removal.

  7. THE FIRST AND ONLY IUD APPROVED FOR HEAVY MENSTRUAL BLEEDING (HMB) FOR UP TO 5 YEARS, FOR PATIENTS WHO CHOOSE AN IUD FOR CONTRACEPTION2 *The safety and efficacy of Mirena in the treatment of HMB (≥80 mL MBL) were studied in a randomized, open-label, parallel-group, active-control trial comparing Mirena (n=79) to oral hormonal therapy